223 related articles for article (PubMed ID: 17664392)
1. Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation.
Maffei A; Di Pardo A; Carangi R; Carullo P; Poulet R; Gentile MT; Vecchione C; Lembo G
Hypertension; 2007 Oct; 50(4):652-6. PubMed ID: 17664392
[TBL] [Abstract][Full Text] [Related]
2. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
[TBL] [Abstract][Full Text] [Related]
3. Effect of DL-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells.
Evangelista S; Garbin U; Pasini AF; Stranieri C; Boccioletti V; Cominacini L
Pharmacol Res; 2007 Apr; 55(4):303-9. PubMed ID: 17280840
[TBL] [Abstract][Full Text] [Related]
4. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker.
Ignarro LJ
Blood Press Suppl; 2004 Oct; 1():2-16. PubMed ID: 15587107
[TBL] [Abstract][Full Text] [Related]
5. Nebivolol-induced vasodilation of renal afferent arterioles involves β3-adrenergic receptor and nitric oxide synthase activation.
Feng MG; Prieto MC; Navar LG
Am J Physiol Renal Physiol; 2012 Sep; 303(5):F775-82. PubMed ID: 22674024
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells.
Ladage D; Brixius K; Hoyer H; Steingen C; Wesseling A; Malan D; Bloch W; Schwinger RH
Clin Exp Pharmacol Physiol; 2006 Aug; 33(8):720-4. PubMed ID: 16895546
[TBL] [Abstract][Full Text] [Related]
7. Nebivolol protects against myocardial infarction injury via stimulation of beta 3-adrenergic receptors and nitric oxide signaling.
Zhang Z; Ding L; Jin Z; Gao G; Li H; Zhang L; Zhang L; Lu X; Hu L; Lu B; Yu X; Hu T
PLoS One; 2014; 9(5):e98179. PubMed ID: 24849208
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide mechanisms of nebivolol.
Maffei A; Lembo G
Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
[TBL] [Abstract][Full Text] [Related]
9. Nebivolol induces eNOS activation and NO-liberation in murine corpus cavernosum.
Reidenbach C; Schwinger RH; Steinritz D; Kehe K; Thiermann H; Klotz T; Sommer F; Bloch W; Brixius K
Life Sci; 2007 Jun; 80(26):2421-7. PubMed ID: 17512554
[TBL] [Abstract][Full Text] [Related]
10. Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1 -selective receptor blockade.
Cosentino F; Bonetti S; Rehorik R; Eto M; Werner-Felmayer G; Volpe M; Lüscher TF
J Hypertens; 2002 Mar; 20(3):421-8. PubMed ID: 11875309
[TBL] [Abstract][Full Text] [Related]
11. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
Gupta S; Wright HM
Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
[TBL] [Abstract][Full Text] [Related]
12. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production.
Broeders MA; Doevendans PA; Bekkers BC; Bronsaer R; van Gorsel E; Heemskerk JW; Egbrink MG; van Breda E; Reneman RS; van Der Zee R
Circulation; 2000 Aug; 102(6):677-84. PubMed ID: 10931809
[TBL] [Abstract][Full Text] [Related]
13. Mixed beta3-adrenoceptor agonist and alpha1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta.
Rozec B; Quang TT; Noireaud J; Gauthier C
Br J Pharmacol; 2006 Apr; 147(7):699-706. PubMed ID: 16474420
[TBL] [Abstract][Full Text] [Related]
14. Effects of nebivolol on human platelet aggregation.
Falciani M; Rinaldi B; D'Agostino B; Mazzeo F; Rossi S; Nobili B; Rossi F; Filippelli A
J Cardiovasc Pharmacol; 2001 Dec; 38(6):922-9. PubMed ID: 11707696
[TBL] [Abstract][Full Text] [Related]
15. Characterization of nitric oxide release by nebivolol and its metabolites.
Maffei A; Vecchione C; Aretini A; Poulet R; Bettarini U; Gentile MT; Cifelli G; Lembo G
Am J Hypertens; 2006 Jun; 19(6):579-86. PubMed ID: 16733229
[TBL] [Abstract][Full Text] [Related]
16. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
Ignarro LJ
Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
[TBL] [Abstract][Full Text] [Related]
17. Beta3-adrenoreceptor stimulation ameliorates myocardial ischemia-reperfusion injury via endothelial nitric oxide synthase and neuronal nitric oxide synthase activation.
Aragón JP; Condit ME; Bhushan S; Predmore BL; Patel SS; Grinsfelder DB; Gundewar S; Jha S; Calvert JW; Barouch LA; Lavu M; Wright HM; Lefer DJ
J Am Coll Cardiol; 2011 Dec; 58(25):2683-91. PubMed ID: 22152956
[TBL] [Abstract][Full Text] [Related]
18. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of platelet nitric oxide production by nebivolol prevents thrombosis.
Momi S; Caracchini R; Falcinelli E; Evangelista S; Gresele P
Arterioscler Thromb Vasc Biol; 2014 Apr; 34(4):820-9. PubMed ID: 24558107
[TBL] [Abstract][Full Text] [Related]
20. No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors.
Chlopicki S; Kozlovski VI; Gryglewski RJ
J Physiol Pharmacol; 2002 Dec; 53(4 Pt 1):615-24. PubMed ID: 12512696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
